"Decadose" Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical Studies

K. Thomas Robbins, Anna Maria Storniolo, William M. Hryniuk, Stephen B. Howell

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

There is evidence that solid tumors rapidly acquire cellular resistance to cisplatin. This resistance is usually mild to moderate and could be circumvented with higher concentrations of drug exposure if ancillary methods were available to avoid systemic cytotoxicity. The purpose of this study was to determine whether a tenfold increase in dose (decadose) would overcome cisplatin resistance. In a clinical trial, response effects of cisplatin at dose intensities ranging from 32.5 to 200 mg/m2 per week, which were delivered by highly selective intraarterial infusions with a simultaneously administered intravenous neutralizing agent, were measured in 31 patients with squamous cell carcinoma (SCC) of the upper aerodigestive tract (UADT). The overall response rate (complete response [CR] and partial response [PR]) to cisplatin therapy at dose intensity intervals of 0 to 74, 75 to 149, and 150 to 200 mg/m2 per week were 45.5%, 72.7%, and 100%, respectively. The average received dose intensities for nonresponders and responders (CR and PR) were 57.8 and 120.7 mg/m2 per week, respectively (P = .031). The results indicate that resistance to standard doses of cisplatin by SCC of the UADT, both previously untreated and recurrent, can be substantially overcome with "decadose" cisplatin therapy. Progress toward improving survival of patients with head and neck cancer, and possibly other site-specific malignancies, may be achieved by incorporating decadose cisplatin therapy into a multimodality treatment plan.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalLaryngoscope
Volume106
Issue number1 I
DOIs
StatePublished - Jan 1996

Fingerprint

Cisplatin
Squamous Cell Carcinoma
Intra Arterial Infusions
Therapeutics
Head and Neck Neoplasms
Clinical Studies
Neoplasms
Clinical Trials
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

"Decadose" Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical Studies. / Robbins, K. Thomas; Storniolo, Anna Maria; Hryniuk, William M.; Howell, Stephen B.

In: Laryngoscope, Vol. 106, No. 1 I, 01.1996, p. 37-42.

Research output: Contribution to journalArticle

Robbins, K. Thomas ; Storniolo, Anna Maria ; Hryniuk, William M. ; Howell, Stephen B. / "Decadose" Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical Studies. In: Laryngoscope. 1996 ; Vol. 106, No. 1 I. pp. 37-42.
@article{b03992f34b1941a2b2e0b37cfc47fada,
title = "{"}Decadose{"} Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical Studies",
abstract = "There is evidence that solid tumors rapidly acquire cellular resistance to cisplatin. This resistance is usually mild to moderate and could be circumvented with higher concentrations of drug exposure if ancillary methods were available to avoid systemic cytotoxicity. The purpose of this study was to determine whether a tenfold increase in dose (decadose) would overcome cisplatin resistance. In a clinical trial, response effects of cisplatin at dose intensities ranging from 32.5 to 200 mg/m2 per week, which were delivered by highly selective intraarterial infusions with a simultaneously administered intravenous neutralizing agent, were measured in 31 patients with squamous cell carcinoma (SCC) of the upper aerodigestive tract (UADT). The overall response rate (complete response [CR] and partial response [PR]) to cisplatin therapy at dose intensity intervals of 0 to 74, 75 to 149, and 150 to 200 mg/m2 per week were 45.5{\%}, 72.7{\%}, and 100{\%}, respectively. The average received dose intensities for nonresponders and responders (CR and PR) were 57.8 and 120.7 mg/m2 per week, respectively (P = .031). The results indicate that resistance to standard doses of cisplatin by SCC of the UADT, both previously untreated and recurrent, can be substantially overcome with {"}decadose{"} cisplatin therapy. Progress toward improving survival of patients with head and neck cancer, and possibly other site-specific malignancies, may be achieved by incorporating decadose cisplatin therapy into a multimodality treatment plan.",
author = "Robbins, {K. Thomas} and Storniolo, {Anna Maria} and Hryniuk, {William M.} and Howell, {Stephen B.}",
year = "1996",
month = "1",
doi = "10.1097/00005537-199601000-00008",
language = "English (US)",
volume = "106",
pages = "37--42",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "1 I",

}

TY - JOUR

T1 - "Decadose" Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical Studies

AU - Robbins, K. Thomas

AU - Storniolo, Anna Maria

AU - Hryniuk, William M.

AU - Howell, Stephen B.

PY - 1996/1

Y1 - 1996/1

N2 - There is evidence that solid tumors rapidly acquire cellular resistance to cisplatin. This resistance is usually mild to moderate and could be circumvented with higher concentrations of drug exposure if ancillary methods were available to avoid systemic cytotoxicity. The purpose of this study was to determine whether a tenfold increase in dose (decadose) would overcome cisplatin resistance. In a clinical trial, response effects of cisplatin at dose intensities ranging from 32.5 to 200 mg/m2 per week, which were delivered by highly selective intraarterial infusions with a simultaneously administered intravenous neutralizing agent, were measured in 31 patients with squamous cell carcinoma (SCC) of the upper aerodigestive tract (UADT). The overall response rate (complete response [CR] and partial response [PR]) to cisplatin therapy at dose intensity intervals of 0 to 74, 75 to 149, and 150 to 200 mg/m2 per week were 45.5%, 72.7%, and 100%, respectively. The average received dose intensities for nonresponders and responders (CR and PR) were 57.8 and 120.7 mg/m2 per week, respectively (P = .031). The results indicate that resistance to standard doses of cisplatin by SCC of the UADT, both previously untreated and recurrent, can be substantially overcome with "decadose" cisplatin therapy. Progress toward improving survival of patients with head and neck cancer, and possibly other site-specific malignancies, may be achieved by incorporating decadose cisplatin therapy into a multimodality treatment plan.

AB - There is evidence that solid tumors rapidly acquire cellular resistance to cisplatin. This resistance is usually mild to moderate and could be circumvented with higher concentrations of drug exposure if ancillary methods were available to avoid systemic cytotoxicity. The purpose of this study was to determine whether a tenfold increase in dose (decadose) would overcome cisplatin resistance. In a clinical trial, response effects of cisplatin at dose intensities ranging from 32.5 to 200 mg/m2 per week, which were delivered by highly selective intraarterial infusions with a simultaneously administered intravenous neutralizing agent, were measured in 31 patients with squamous cell carcinoma (SCC) of the upper aerodigestive tract (UADT). The overall response rate (complete response [CR] and partial response [PR]) to cisplatin therapy at dose intensity intervals of 0 to 74, 75 to 149, and 150 to 200 mg/m2 per week were 45.5%, 72.7%, and 100%, respectively. The average received dose intensities for nonresponders and responders (CR and PR) were 57.8 and 120.7 mg/m2 per week, respectively (P = .031). The results indicate that resistance to standard doses of cisplatin by SCC of the UADT, both previously untreated and recurrent, can be substantially overcome with "decadose" cisplatin therapy. Progress toward improving survival of patients with head and neck cancer, and possibly other site-specific malignancies, may be achieved by incorporating decadose cisplatin therapy into a multimodality treatment plan.

UR - http://www.scopus.com/inward/record.url?scp=0030062961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030062961&partnerID=8YFLogxK

U2 - 10.1097/00005537-199601000-00008

DO - 10.1097/00005537-199601000-00008

M3 - Article

C2 - 8544625

AN - SCOPUS:0030062961

VL - 106

SP - 37

EP - 42

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 1 I

ER -